Chris Lyons+FollowSarepta’s Gene Therapy Drama: What’s Really Up?Wild update in the biotech world: An 8-year-old in Brazil died after getting Sarepta’s Elevidys gene therapy for Duchenne muscular dystrophy, but both Sarepta and Roche are saying it wasn’t the treatment—looks like a bad flu was to blame. Still, the FDA is digging in, and Brazil has paused all Elevidys sales just in case. Sarepta’s stock took another hit, and everyone’s now questioning how safe these gene therapies really are. Big pharma drama! #Health #BodyHealth #biotechnews00Share
Kim Reeves+FollowBiotech Plot Twist: Sage Gets a New HomeHere’s a coffee break scoop: Sage Therapeutics, once a biotech darling, just got snapped up by Supernus for up to $795M—way more than Biogen’s earlier lowball offer. After a rollercoaster ride (think: stock price nosedives and legal drama), Sage’s postpartum depression drug is now Supernus’ ticket to a bigger medicine cabinet. For everyday investors, it’s a reminder that sometimes, holding out for a better deal pays off—even if the story doesn’t end with fireworks. #BiotechNews #Investing #Acquisition #Business #EntrepreneurshipStartup10Share
Jacqueline Howard DDS+FollowGene Therapy Drama: 2nd Death Shakes SareptaSarepta’s gene therapy for muscular dystrophy just hit another major snag—a second teen has died from liver injury after treatment. The company’s now pausing shipments for older, non-walking patients and rethinking safety protocols. The FDA might step in and tighten the rules or even pull the drug for some patients. Wild part? This one-time treatment costs $3.2 million. Wall Street’s freaking out, and Sarepta’s stock just tanked 42%. Stay tuned for more twists. #GeneTherapy #MuscularDystrophy #BiotechNews #Health #BodyHealth50Share
shermandarlene+FollowAmgen’s Cancer Drug Shows Big PromiseAmgen just dropped some major news: their new drug Imdelltra cut the risk of death by 40% for small cell lung cancer patients who didn’t respond to chemo. Plus, people lived over 5 months longer on average compared to standard treatment. Even symptoms like cough and shortness of breath improved! But here’s the twist—despite the breakthrough, retail investors aren’t exactly hyped yet. Would you bet on Amgen after this? #Amgen #CancerResearch #BiotechNews #Health2776Share
Ryan Lewis+FollowCancer Breakthrough Lasts Nearly 4 Years!UroGen just dropped some wild data: their JELMYTO treatment for a rare urinary tract cancer is keeping patients cancer-free for almost four years on average! Even better, it works whether the cancer is new or coming back. This is the first FDA-approved non-surgical option for this cancer, and the results are so strong that analysts are hyped on the stock. Biotech is seriously having a moment, and this could be a game-changer for patients who want to avoid surgery. #CancerBreakthrough #BiotechNews #UroGen #CancerResearch #Oncology #MedicalInnovation #Health2869Share
